1673516-98-7
1673516-98-7 structure
- Name: Relatlimab
- Chemical Name: Relatlimab
- CAS Number: 1673516-98-7
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2022-10-16 12:17:09
- Modify Date: 2025-08-25 21:38:54
-
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer[1].
| Name | Relatlimab |
|---|
| Description | Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Relatlimab (BMS-986016; 0.001-100 nM) recognizes native LAG-3 and binds to primary activated human and cynomolgus CD4+ T cells with EC50 values of 0.11 nM and 29.11 nM, respectively[1]. Relatlimab (0.001-10000 nM; T cells (3A9-hLAG-3)) enhances peptide responsiveness of T-cell hybridoma 3A9-hLAG-3 and reversals LAG-3-mediated inhibition of T-cell hybridoma 3A9-hLAG-3 with an IC50 value of 1.05 nM[1]. Relatlimab (0.001-10000 nM; primary T cells) enhances activation of superantigen-stimulated human PBMC cultures and enhances IL-2 secretion[1]. |
| References |
| No Any Chemical & Physical Properties |